InMed Pharmaceuticals Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
PART I – FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
PART I
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.
Unaudited Condensed Consolidated Financial Statements of
For the Three and Nine Months Ended March 31, 2026 and 2025
(Expressed in U.S. Dollars)
March 31, 2026
| INDEX | Page | |
|---|---|---|
| Financial Statements | ||
| ● | Condensed Consolidated Balance Sheets as of March 31, 2026 (unaudited) and June 30, 2025 | 3 |
| ● | Condensed Consolidated Statements of Operations for the Three and Nine Months Ended March 31, 2026 and 2025 (unaudited) | 4 |
| ● | Condensed Consolidated Statements of Shareholders’ Equity for the Three and Nine Months Ended March 31, 2026 and 2025 (unaudited) | 5 |
| ● | Condensed Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2026 and 2025 (unaudited) | 6 |
| ● | Notes to the Condensed Consolidated Financial Statements | 7-20 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.